Evidence map›Paper›PMID 26335606›Full record

ArticleBritish journal of cancer2015

Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers.

Ruth Exner, Walter Pulverer, Martina Diem, Lisa Spaller, Laura Woltering, Martin Schreiber, Brigitte Wolf, Markus Sonntagbauer, Fabian Schröder, Judith Stift and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ruth ExnerDepartment of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Walter PulvererAIT-Austrian Institute of Technology GmbH, Health & Environment Department, Molecular Diagnostics, Muthgasse 11/2, A-1190 Vienna, Austria.
Martina DiemClinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Lisa SpallerClinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Laura WolteringClinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Martin SchreiberDepartment of Obstetrics and Gynecology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Brigitte WolfDepartment of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Markus SonntagbauerAIT-Austrian Institute of Technology GmbH, Health & Environment Department, Molecular Diagnostics, Muthgasse 11/2, A-1190 Vienna, Austria.
Fabian SchröderAIT-Austrian Institute of Technology GmbH, Health & Environment Department, Molecular Diagnostics, Muthgasse 11/2, A-1190 Vienna, Austria.
Judith StiftClinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Fritz WrbaClinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Michael BergmannDepartment of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Andreas WeinhäuselAIT-Austrian Institute of Technology GmbH, Health & Environment Department, Molecular Diagnostics, Muthgasse 11/2, A-1190 Vienna, Austria.
Gerda EggerClinical Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

Funding

Austrian Science Fund FWF P 27616
6 · The paper itself

Abstract

backgroundAberrant DNA methylation is more prominent in proximal compared with distal colorectal cancers. Although a number of methylation markers were identified for colon cancer, yet few are available for rectal cancer.

methodsDNA methylation differences were assessed by a targeted DNA microarray for 360 marker candidates between 22 fresh frozen rectal tumour samples and 8 controls and validated by microfluidic high-throughput and methylation-sensitive qPCR in fresh frozen and formalin-fixed paraffin-embedded (FFPE) samples, respectively. The CpG island methylator phenotype (CIMP) was assessed by MethyLight in FFPE material from 78 patients with pT2 and pT3 rectal adenocarcinoma.

resultsWe identified and confirmed two novel three-gene signatures in fresh frozen samples that can distinguish tumours from adjacent tissue as well as from blood with a high sensitivity and specificity of up to 1 and an AUC of 1. In addition, methylation of individual CIMP markers was associated with specific clinical parameters such as tumour stage, therapy or patients' age. Methylation of CDKN2A was a negative prognostic factor for overall survival of patients.

conclusionsThe newly defined methylation markers will be suitable for early disease detection and monitoring of rectal cancer.

Indexed as

DNA MethylationAdultAgedAged, 80 and overBiomarkers, TumorCpG IslandsCyclin-Dependent Kinase Inhibitor p16DNA, NeoplasmFemaleHumansMaleMiddle AgedNeoplasm ProteinsOligonucleotide Array Sequence AnalysisPrognosisRectal NeoplasmsBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16DNA, NeoplasmNeoplasm Proteins

Identifiers

PMID26335606
PMCPMC4651135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.